Where does Sutro Biopharma, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sutro Biopharma, Inc. ranks #6,488 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sutro Biopharma, Inc. hold?

Sutro Biopharma, Inc. holds 52 US utility patents granted between 2015 and 2025, spanning 12 technology areas.

What is Sutro Biopharma, Inc.'s Innovation Score?

Sutro Biopharma, Inc. has an Innovation Score of 44.2 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Sutro Biopharma, Inc. focus on?

Sutro Biopharma, Inc.'s top technology area is C07K (Peptides) with 41 patents, ranking #231 of 3,615 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Sutro Biopharma, Inc.'s patent grant rate increasing or decreasing?

Sutro Biopharma, Inc.'s recent grant velocity is +32% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Sutro Biopharma, Inc.'s patents?

Sutro Biopharma, Inc.'s patents average 22.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sutro Biopharma, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Sutro Biopharma, Inc.

USPTO PatentsView assignee record - 52 granted patents across 12 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Sutro ranks #6,488 of 49,997 tracked US assignees by granted-patent volume, with 52 patents across 12 technology areas.

#6,488
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.2/100): 22.7
avg claims per patent: +32%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6488 · US Corporation #6,488 · 52 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 52 grants
UPPER-Q #6,488/49,997
PHOTO-FINISH Sartorius Stedim…
CPC-FOCUS C07K · 12 areas
INNOV-PAR 44.2/100
CLAIMS-DENSE 22.7 claims/avg
TYPE-USCORP US Corporation
VEL-UP +32% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Sartorius Stedim North America Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Sutro’s 44.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.7 pts (31%) Velocity 4.6 pts (10%) Breadth 12.2 pts (28%) Claim depth 13.6 pts (31%)

Qualcomm Incorporated · highest

85
Cetres Holdings · near

44
Hy-ko Products · near

44
Integenx · near

44
Sutro Biopharma · this assignee

44
Roche Diagnostics… · near

44
3D Lighting… · lowest

7

What this shows Sutro's Innovation Score is 44.2/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Sutro?

Each dot is one of Sutro’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Sutro’s own 22.7 claims/patent is ABOVE the 10.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Sutro vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Sutro's grants concentrate

Sutro Biopharma, Inc. is a focused PatentsView assignee: 12 CPC subclasses with 78.8% of grants classified under C07K (Peptides). Peak complete grant year is 2020 (8 grants) versus a trough of 1 in 2015. By volume, Sutro sits between Soremartec S.A. and Toyo Tanso Co., Ltd..

Sutro's three-year grant acceleration

Sutro Biopharma, Inc. shows 13 grants in 2022–2024 against only 19 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Soremartec

52
Sartorius Stedim…

52
Sharp Life Scienc…

52
Sun Hydraulics

52
Technology Resear…

52
THE Gleason Works

52
Toyo Aluminium

52
Toyo Tanso

52
Sutro Biopharma ◀

52

What this shows Sutro holds 52 patents at rank #6,488, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sutro

By rank, the assignees closest to #6,488 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Sutro's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Sutro, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Sutro ranks #231 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Cetres Holdings, LLC 44 Integenx Inc. 44 Hy-ko Products Company LLC 44 Roche Diagnostics International AG 44

Similar claim depth

Nearest assignees by average claims per patent (22.7 here).

Bal Seal Engineering, LLC 22.7 avg Electrocore, Inc. 22.7 avg Technoprobe S.P.A. 22.8 avg Allosource 22.8 avg

Sutro's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Sutro Biopharma, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	1.9%
2017	6	11.5%
2018	5	9.6%
2019	7	13.5%
2020	8	15.4%
2021	4	7.7%
2022	4	7.7%
2023	3	5.8%
2024	6	11.5%
2025partial year	8	15.4%

Which technologies does Sutro Biopharma, Inc. patent most?

C07K - Peptides 41

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 25

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 23

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 22

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 19

C12Y - Enzymes 11

C07D - Heterocyclic Compounds 11

C07C - Acyclic OR Carbocyclic Compounds 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 2

C12R - Indexing Scheme Associated With Subclasses C12c - C12q, Relating TO Microorganisms 2

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Sutro Biopharma, Inc.'s patent record in context - here's where to go next.

Sutro Biopharma, Inc.'s lead technology class is C07K (Peptides), 78.8% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #6,488 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Sutro Biopharma, Inc. against Soremartec S.A., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.